Rosiglitazone treatment in zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury

Diabetes

Volumn 54, Issue 2, 2005, Pages 554-562

  Yue, Tian Li ^a   Bao, Weike ^a   Gu, Juan Li ^a   Cui, Jianqi ^a   Tao, Ling ^a,b   Ma, Xin Liang ^a,b   Ohlstein, Eliot H ^a   Jucker, Beat M ^a  

^a GLAXOSMITHKLINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; ROSIGLITAZONE; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; WORTMANNIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOWNSTREAM PROCESSING; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART PROTECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HEART; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 12744268367     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.2.554     Document Type: Article

References (40)

1. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaption of the heart in diabetes. Part I. General concepts. Circulation 105:1727-1733, 2002
2. Takahashi N, Iwasaka T, Sugiura T, Hasegawa T, Tarumi N, Kimura Y, Kurihara S, Onoyama H, Inada M: Left ventricular regional function after acute anterior myocardial infarction in diabetic patients. Diabetes Care 12:630-635, 1989
3. Iwasaka T, Takahashi N, Nakamura S, Sugiura T, Tarumi N, Kimura Y, Okubo N, Taniguchi H, Matsui Y, Inada M: Residual left ventricular pump acute myocardial infarction in NIDDM patients. Diabetic Care 15:1522-1526, 1992
4. O'Connor CM, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM: Clinical characteristics and long-term outcome in patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J 133:663-673, 1997
5. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69-75, 1998
6. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anverse P: Myocardial cell death in human diabetes. Circ Res 87:1123-1132, 2000
7. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 28:1661-1669, 1996
8. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR: The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42:914-922, 2003
9. Utriainen T, Takala T, Luotolahti M: Insulin resistance characterizes glucose uptake in skeletal muscle but not the heart in NIDDM. Diabetologia 41:555-559, 1998
10. Zaninetti D, Greco-Perotto R, Assimacopoulos-Jeannet F, Jeanrenaud B: Dysreglution of glucose transport and transporters in perfused hearts of genetically obese (fa/fa) rats. Diabetologia 32:56-60, 1989
11. Volpio-Pulkki L-M, Nuutila P, Knuuti MJ, Ruotsalainen U, Haaparanta M, Teras M, Wegelius U, Koiviso VA: Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography. J Nucl Med 34:2064-2067, 1993
12. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Kadda GK, Ferrannini E: Cardiac and skeletal muscle insulin resistance in patients with coronary heart diseases: a study with positron emission tomography. J Clin Invest 98:2094-2099, 1996
13. Ohtake T, Yokoyama I, Watanabe T, Momose T, Serezawa T, Nishikawa J, Sasaki Y: Myocardial glucose metabolism in non-insulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 36:456-463, 1995
14. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH: Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 103:1734-1739, 2001
15. Lopaschuk GD, Saddik M, Barr R, Huang L, Barder DD, Muzyke RA: Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am J Physiol 263:E1046-E1053, 1992
16. Paulson DJ: The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34:104-112, 1997
17. Feuvray D, Lopaschuk GD: Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 34:113-120, 1997
18. Wang P, Chatham JC: Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 286:E725-E736, 2004
19. Zhu P, Lu L, Xu Y, Schwartz GG: Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101:1165-1171, 2000
20. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588-2594, 2001
21. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C: Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J 16:1027-1040, 2002
22. Ito H, Nakano A, Kinoshita M, Matsumori A: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83:1715-1721, 2003
23. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K: Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51:1110-1117, 2002
24. 2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51:1507-1514, 2002
25. 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat. J Biol Chem 272:10464-10473, 1997
26. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion. Circulation 105:1497-1502, 2000
27. Yue TL, Ma XL, Wang XK, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste George, Ruffolo RR, Feuerstein GZ: Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82:166-174, 1998
28. Malhotra R, Brosius FC: Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal cardiac myocytes. J Biol Chem 274:12567-12575, 1999
29. Temsah RM, Netticadan T, Kawabata K-I, Dhalla NS: Lack of oxygen and glucose contributes to I/R-induced changes in cardiac SR function. Am J Physiol (Cell Physiol) 283:C1306-C1312, 2002
30. Van Rooyen J, McCarthy J, Opie LH: Increased glycolysis during ischemia mediates the protective effect of glucose and insulin in the isolated rat heart despite the presence of cardiodepressant exogenous substrates. Cardiovasc J S Afr 13:103-109, 2002
31. Van Der Vusse GJ, Glatz JFC, Stam CG, Reneman RS: Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 72:881-940, 1992
32. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Cavies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I: A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304:1325-1328, 2004
33. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292:1728-1731, 2001
34. Garofalo RS, Orena SJ, Pafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD, Coleman KG: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J Clin Invest 112:197-208, 2003
35. Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, Nagai R, Komuro I: Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation 102:2873-2879, 2000
36. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769-776, 2001
37. Pap M, Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol-3-kinase/Akt cell survival pathway. J Biol Chem 273:19929-19932, 1998
38. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3β in cell survival and NF-kB activation. Nature 406:86-90, 2000
39. Tong H, Imahashi K, Steenbergen C, Murphy E: Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotection. Circ Res 90:377-379, 2002
40. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868, 1999